NexImmune, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NEXI research report →
About the company
NexImmune, Inc. , a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases in the United States. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a vivo directly injectable modality platform.
- CEO
- Craig R. Jalbert
- IPO
- 2021
- Employees
- 6
- HQ
- Gaithersburg, MD, US
Price Chart
- Market Cap
- $139
- P/E
- -0.00
- P/S
- 0.00
- P/B
- 0.00
- EV/EBITDA
- 0.11
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -180.64%
- ROIC
- -800.38%
- Revenue
- $0 · 0.00%
- Net Income
- $-32,344,392 · -106.29%
- EPS
- $-30.82 · -105.77%
- Op Income
- $-29,192,480
- FCF YoY
- 39.98%
- 52W High
- $1.01
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- 3.71
- Avg Volume
- 446
Get TickerSpark's AI analysis on NEXI
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 11, 24 | Jones Kristi | buy | 1 |
| Apr 5, 24 | Marchio Albert N II | other | 0 |
| Nov 21, 23 | Roemer Alan S. | sell | 3,833 |
| Nov 22, 23 | Roemer Alan S. | sell | 3,992 |
| Aug 30, 23 | STOVER TIMOTHY | other | 0 |
| Aug 30, 23 | STOVER TIMOTHY | other | 11,625 |
| Aug 30, 23 | STOVER TIMOTHY | other | 6,375 |
| Jul 5, 23 | Verstandig Grant | other | 44,983 |
| Jul 5, 23 | Gandhi Leena | other | 44,983 |
| Jul 5, 23 | Yao Zhengbin | other | 44,983 |
Our NEXI coverage
Recent articles, reports, and earnings notes.
No research on NEXI yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate NEXI report →Similar companies
Peers in the same neighborhood.